Multienzyme Complexes Or Mixtures Of Enzymes Patents (Class 424/94.2)
-
Patent number: 8784884Abstract: Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.Type: GrantFiled: September 28, 2009Date of Patent: July 22, 2014Inventors: Stephen Perrett, Ruth Thieroff-Ekerdt, Gopi Venkatesh, Konstantinos Efthymiopoulos
-
Patent number: 8784856Abstract: Particular aspects provide methods for converting glucosinolate in a glucosinolate-containing plant material to glucosinolate breakdown products (GBPs), comprising: providing an amount of processed glucosinolate-containing plant material, the processed material being depleted of oil and glucosinolate converting enzyme activity by virtue of said processing; providing an amount of glucosinolate converting enzyme activity; mixing the processed material with the amount enzyme activity; hydrating the mixture; and incubating the hydrated mixture, wherein the glucosinolates are enzymatically converted to GBPs. Preferably, the processed plant material comprises a oilseed-derived seedmeal material (e.g., meadowfoam seedmeal) from which the oil has been removed by the processing (e.g., solvent extraction and/or heat treatment). In particular embodiments, the glucosinolate converting enzyme activity comprises at least one of a myrosinase activity and a nitrile-forming activity.Type: GrantFiled: July 21, 2008Date of Patent: July 22, 2014Assignee: The State of Oregon Acting by and Through the State Boad of Higher Education on Behalf of Oregon State UniversityInventors: Jan F. Stevens, Stephen Machado, Ralph Reed, Michael S. Martinez
-
Patent number: 8778335Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.Type: GrantFiled: March 11, 2008Date of Patent: July 15, 2014Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 8772240Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.Type: GrantFiled: May 17, 2007Date of Patent: July 8, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
-
Publication number: 20140186436Abstract: The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can be used in methods designed to lower blood alcohol levels in vivo, and/or to break down the toxic byproducts of alcohol metabolism. Consequently these nanocomplexes can be used to treat a variety of conditions resulting from the consumption of alcohol, including for example, acute alcohol intoxication.Type: ApplicationFiled: July 6, 2012Publication date: July 3, 2014Applicant: The Regents of the University of CaliforniaInventors: Otto O. Yang, Yunfeng Lu, Cheng Ji, Ming Yan, Yang Liu
-
Patent number: 8765144Abstract: The present invention provides a purified multimeric complex from P. gingivalis. The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.Type: GrantFiled: November 11, 2010Date of Patent: July 1, 2014Assignee: The University of MelbourneInventors: Eric Charles Reynolds, Neil Martin O'Brien-Simpson, Rishi Delan Pathirana
-
Publication number: 20140170212Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: October 2, 2013Publication date: June 19, 2014Applicant: APTALIS PHARMA LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20140154229Abstract: The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease.Type: ApplicationFiled: July 19, 2012Publication date: June 5, 2014Inventors: Lior Rosenberg, Guy Rubin, Eilon Asculai
-
Publication number: 20140140987Abstract: A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin. The method further comprises administering an effective amount of a protein containing ApoA1/2/4, or administering an effective amount of a protein containing Factor II, Factor VII, Factor IX and Factor X in prothrombin complex concentrate. The method can further comprise administering an effective amount of fibrinogen, Factor VIII, high concentrate fibrinogen, thrombin. hepatitis B immune globulin (HBIG), anti-thrombin III (AT-III), protein C, fibronectin, protein S and protein M.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Publication number: 20140140975Abstract: The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: Universiteit Maastricht, The University of Vermont and State Agricultural CollegeInventors: Yvonne M. Janssen-Heininger, Niki Reynaert, Vikas Anathy, Scott Aesif
-
Patent number: 8728754Abstract: Provided herein are proteins derived from Pseudomonas sp., particularly Pseudomonas protegens, compositions comprising said proteins and their use in controlling molluscidal activity.Type: GrantFiled: March 15, 2013Date of Patent: May 20, 2014Assignee: Marrone Bio Innovations, Inc.Inventors: Huazhang Huang, Ratnakar Asolkar, Pamela Marrone, Ana Lucia Cordova-Kreylos
-
Patent number: 8728467Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: GrantFiled: March 25, 2011Date of Patent: May 20, 2014Assignee: Prothera Inc.Inventor: Stephen Francis Olmstead
-
Publication number: 20140134146Abstract: The present application discloses a fouling release cured paint coat comprising a polysiloxane-based binder matrix constituting at least 40% by dry weight of the coat, and one or more enzymes. The application further discloses a kit for preparing a fouling release coat, a coating composition comprising a polysiloxane-based binder system comprising one or more polysiloxane components modified with hydrophilic oligomer/polymer moieties, and one or more enzymes, and a coating composition comprising a polysiloxane-based binder system, 0.01-20% by dry weight of one or more hydrophilic-modified polysiloxane oils, and one or more enzymes.Type: ApplicationFiled: June 29, 2012Publication date: May 15, 2014Applicant: HEMPEL A/SInventors: Stefan Møller Olsen, Diego Meseguer Yebra
-
Publication number: 20140134213Abstract: The present application relates to an anti-microbial system for use in the treatment of microbial infections or control of microbial contamination, which avoids the use of antibiotics. Such infections include mastitis, tuberculosis, cystic fibrosis and the contamination that may result from biofilm formation on medical devices.Type: ApplicationFiled: April 16, 2012Publication date: May 15, 2014Inventors: Vincent O'Flaherty, Paul McCay
-
Publication number: 20140127180Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.Type: ApplicationFiled: May 4, 2012Publication date: May 8, 2014Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Isabelle De Waziers, Walid Touati, Monique Diry, Jean-Pierre Flinois, Patrick Dansette, Philippe Beaune
-
Patent number: 8715647Abstract: The use is provided composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative of any thereof. Such endoglucanases may be obtained from a genetically modified strain of the fungus Trichoderma. Also provided is an enzyme-based feed additive which comprises EGI and/or EGII which lack the cellulose binding domain, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. A further enzyme-based feed additive is provided which comprises a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.Type: GrantFiled: August 5, 2005Date of Patent: May 6, 2014Assignee: Danisco US Inc.Inventors: Michael R. Bedford, Andrew J. Morgan, Timothy Fowler, Kathleen A. Clarkson, Michael Ward, Katherine D. Collier, Edmund A. Larenas
-
Patent number: 8715994Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 16, 2012Date of Patent: May 6, 2014Assignees: Novozymes A/S, Novozymes Inc.Inventor: Marc Dominique Morant
-
Patent number: 8709386Abstract: Isolated ?-glucanases from Hypocrea tawa, Trichoderma reesei, and Trichoderma konilangbra are described, as well as oral care compositions containing the same. The oral care composition may be employed to prevent or reduce dental plaque.Type: GrantFiled: April 9, 2009Date of Patent: April 29, 2014Assignee: Danisco US Inc.Inventors: Steven Kim, Suzanne Lantz, Michael Pepsin
-
Patent number: 8709776Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 16, 2012Date of Patent: April 29, 2014Assignees: Novozymes A/S, Novozymes Inc.Inventor: Marc Dominique Morant
-
Publication number: 20140105880Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain harrier.Type: ApplicationFiled: August 16, 2013Publication date: April 17, 2014Inventors: Christopher M. Starr, Todd Zankel
-
Patent number: 8697066Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.Type: GrantFiled: January 31, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
-
Patent number: 8697425Abstract: The present invention relates to a composite yeast for high concentration alcohol fermentation, which includes thermostable Saccharomyces cerevisiae, acid protease, phytase, cellulose, ?-glucanase, and pectinase, and is suitable for the high concentration alcohol fermentation for various raw materials. In addition to normal fermentation, the composite yeast of the present invention can degrade the raw materials, increase the nutrient ingredients in the mash, promote the growth of yeast and provide stress tolerance protection.Type: GrantFiled: December 30, 2005Date of Patent: April 15, 2014Assignee: Angel Yeast Co., Ltd.Inventors: Xuefeng Yu, Zhihong Li, Minghua Yu, Juan Yao, Zhijun Li, Daiwu Liu
-
Patent number: 8673972Abstract: Methods of treating a head and neck cancer are disclosed.Type: GrantFiled: August 2, 2013Date of Patent: March 18, 2014Assignees: Foundation Medicine, Inc., UCL Business PLCInventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Roman Yelensky, Garrett Michael Frampton
-
Publication number: 20140044694Abstract: The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease.Type: ApplicationFiled: April 27, 2012Publication date: February 13, 2014Applicant: OSAKA UNVERSITYInventors: Keiichi Ozono, Takanobu Otomo, Norio Sakai
-
Publication number: 20140030324Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one ore more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.Type: ApplicationFiled: June 17, 2013Publication date: January 30, 2014Applicants: The Milton J. Allison Revocable Trust, OxThera, Inc.Inventors: Harmeet Sidhu, Milton J. Allison
-
Patent number: 8637292Abstract: The present invention relates to isolated polypeptides having esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: January 15, 2010Date of Patent: January 28, 2014Assignee: Novozymes A/SInventors: Dan Pettersson, Wenping Wu, Lan Tang, Ye Liu
-
Patent number: 8632769Abstract: Preferred embodiments of the present invention relate to proteolytic enzyme formulations. More specifically, several embodiments relate to a proteolytic formulation to facilitate digestion, metabolism, degradation of target compounds, and systemic enzymatic action. Embodiments for improving oxygenation and reducing plaque are also provided.Type: GrantFiled: August 30, 2012Date of Patent: January 21, 2014Inventor: Jon Barron
-
Publication number: 20140017220Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.Type: ApplicationFiled: July 1, 2013Publication date: January 16, 2014Applicant: Osio Corporation d/b/a Yolia HealthInventor: Alberto Osio Sancho
-
Publication number: 20140004094Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: December 13, 2012Publication date: January 2, 2014Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock, Bo Yu, Thomas L. Wegman
-
Patent number: 8613918Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.Type: GrantFiled: May 25, 2012Date of Patent: December 24, 2013Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20130337062Abstract: The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.Type: ApplicationFiled: May 1, 2013Publication date: December 19, 2013Applicant: Aptalis Pharma Canada Inc.Inventor: Aptalis Pharma Canada Inc.
-
Publication number: 20130336946Abstract: The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection.Type: ApplicationFiled: February 1, 2011Publication date: December 19, 2013Applicant: TIANJIN XIJI BIOTECHNOLOGY CO., LTD.Inventors: Pingfan Rao, Shutao Liu
-
Patent number: 8609087Abstract: Compounds and methods for designing and identifying compounds which inhibit TFPP-like aspartyl protease enzymes by targeting the aspartic acid residues of the active site or mimicking peptides corresponding to the region surrounding the substrate's cleavage site are provided. Agents identified as inhibitors of TFPP-like aspartyl proteases such as type 4 prepilin peptidases are expected to be useful as anti-bacterial agents and in inhibiting development of drug resistant strains of bacteria.Type: GrantFiled: March 4, 2005Date of Patent: December 17, 2013Assignee: Trustees of Dartmouth CollegeInventors: Ronald K. Taylor, Christian F. LaPointe
-
Patent number: 8603464Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.Type: GrantFiled: November 17, 2010Date of Patent: December 10, 2013Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20130323219Abstract: The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight.Type: ApplicationFiled: May 22, 2013Publication date: December 5, 2013Applicant: Imarko Research S.A.Inventor: Max ROMBI
-
Publication number: 20130323223Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.Type: ApplicationFiled: March 15, 2013Publication date: December 5, 2013Applicant: CUREMARK, LLCInventors: Joan M. FALLON, Matthew F. HEIL, James SZIGETHY, James J. FALLON
-
Publication number: 20130302411Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: November 14, 2013Inventors: Daniel Henry WYROBNIK, Isaac Harry Wyrobnik
-
Patent number: 8568712Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.Type: GrantFiled: January 24, 2013Date of Patent: October 29, 2013Assignee: Master Supplements, Inc.Inventors: Randolph S. Porubcan, Sonja Lea Yonak
-
Publication number: 20130280228Abstract: The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.Type: ApplicationFiled: April 16, 2013Publication date: October 24, 2013Inventors: MAI FAURSCHOU ISAKSEN, RIKKE HOEGH LORENTSEN, PETER PLUMSTEAD, LUIS FERNANDO ROMERO MILLAN, SUSAN MADRID, CHERRY LIN, MICHAEL WARD, MASOUD RAJABI ZARGAHI
-
Publication number: 20130273020Abstract: Compositions are described with an unexpectedly greater yeast growth inhibitory effect than the individual components alone. The compositions include a mixture of honey, a honey analogue or a honey fraction along with lactoferrin protein. The combination has a synergistic effect in inhibiting yeast growth.Type: ApplicationFiled: August 29, 2011Publication date: October 17, 2013Applicant: COMVITA NEW ZEALAND LIMITEDInventors: Swapna Gannabathula, Jonathan McDonald Counsell Stephens
-
Publication number: 20130266552Abstract: A liquid surfactant preparation comprises a phosphonate and has an advantageous lipolytic activity. This is achieved by using a lipase that is naturally present in a microorganism, the microorganism being Rhizopus oryzae or Mucor javanicus.Type: ApplicationFiled: June 20, 2013Publication date: October 10, 2013Inventors: Karl-Heinz Maurer, Timothy O'Connell, Petra Siegert, Thomas Weber, Susanne Tondera, Hendrik Hellmuth
-
Publication number: 20130259848Abstract: Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure.Type: ApplicationFiled: May 23, 2013Publication date: October 3, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Benjamin Simon ELKIN, Barclay MORRISON, III, John Desmond Finan
-
Patent number: 8540983Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.Type: GrantFiled: February 6, 2012Date of Patent: September 24, 2013Assignee: MediWound Ltd.Inventors: Marian Gorecki, Amir Toren
-
Publication number: 20130236439Abstract: Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.Type: ApplicationFiled: February 26, 2013Publication date: September 12, 2013Applicant: LifeCell CorporationInventors: Wenquan Sun, Xiaohua Yu
-
Patent number: 8524226Abstract: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. The invention further includes methods for prolonging patency of hemodialysis access.Type: GrantFiled: February 7, 2011Date of Patent: September 3, 2013Assignee: Proteon Therapeutics, Inc.Inventor: F. Nicholas Franano
-
Publication number: 20130224171Abstract: 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed.Type: ApplicationFiled: November 12, 2012Publication date: August 29, 2013Applicant: PRO NATURA GESELLSCHAFT FUR GESUNDE ERNAHRUNG MBHInventor: Pro Natura Gesellschaft Fur Gesunde Ernahrung
-
Publication number: 20130224172Abstract: Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.Type: ApplicationFiled: January 3, 2013Publication date: August 29, 2013Applicant: CUREMARK, LLCInventor: CUREMARK, LLC
-
Publication number: 20130202581Abstract: Compositions and methods of using the compositions for wound healing are provided. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. The compositions can be formulated as topical pharmaceutical compositions and can be used for faster healing through stimulation of epidermal cells in the absence of scarring. The compositions may deposit a short term fibrosis and help prevent re-opening of wounds. The compositions may improve recruitment of white blood cells, thereby inducing or enhancing growth factor and immune system activation via an enzyme antibiotic effect. The compositions may enhance the epidermal integrity beyond that of the normal physiological restorative process. Application of the compositions may result in greater re-growth of hair on regions of wounds healed with enzyme and reduced alopecia. The compositions may be administered without causing allergic reactions and without causing biological damage or burns.Type: ApplicationFiled: February 1, 2013Publication date: August 8, 2013Applicant: CURELON LLCInventor: Curelon LLC
-
Publication number: 20130202564Abstract: This invention provides a composition for controlled-release of polypeptide growth factors useful in tissue repair or engineering. The composition include a polypeptide growth factor covalently cross-linked to a biocompatible substrate by a transgultaminase. The cross-linking tethers the growth factor to a substrate so that it will not diffuse away from the desired site of application. It also concomitantly inactivates the growth factor. Release and reactivation of the growth factor can be achieved by endogenously produced metalloproteinase (MMPs) or exogenously provided proteases such as collagenases.Type: ApplicationFiled: April 8, 2011Publication date: August 8, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Bo Han, Kenrick Kuwahara
-
Publication number: 20130202695Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Inventors: Daniel Henry WYROBNIK, Isaac Harry Wyrobnik